June 29, 2017 / 12:40 PM / 2 months ago

BRIEF-Celltrion and Teva announce FDA acceptance of BLA for CT-P10

June 29 (Reuters) - Teva Pharmaceutical Industries Ltd

* Celltrion and teva announce u.s. Fda acceptance of biologics license application for proposed biosimilar to rituxan® (rituximab)

* Teva pharmaceutical - ‍bla for ct-p10 has been accepted for filing by fda for standard review, with fda regulatory action expected during q1 of 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below